Evidence map›Paper›PMID 32467173›Full record

ArticleMolecular cancer research : MCR2020

PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

Michael I Dougherty, Christine E Lehman, Adam Spencer, Rolando E Mendez, Abel P David, Linnea E Taniguchi, Julie Wulfkuhle, Emanuel F Petricoin, Daniel Gioeli, Mark J Jameson

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michael I Dougherty *Department of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.ORCID 0000-0003-3682-336X
Christine E Lehman *Department of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
Adam SpencerDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
Rolando E MendezDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
Abel P DavidDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.ORCID 0000-0003-1687-8240
Linnea E TaniguchiDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
Julie WulfkuhleCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia.
Daniel GioeliDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia.
Mark J JamesonDepartment of Otolaryngology - Head & Neck Surgery, University of Virginia School of Medicine, Charlottesville, Virginia. mark.jameson@virginia.edu.
University of Virginia · USGeorge Mason University · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Growth Factor-Induced Resistance to Targeted Therapy in Oral Cavity CancerK08DE019477 · NIDCR · UNIVERSITY OF VIRGINIA · PI JAMESON, MARK J · 2009 to 2013
$540k
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA009109NIDCR NIH HHS K08 DE019477
6 · The paper itself

Abstract

EGFR inhibitors have shown poor efficacy in head and neck squamous cell carcinoma (HNSCC) with demonstrated involvement of the insulin-like growth factor-1 receptor (IGF1R) in resistance to EGFR inhibition. IGF1R activates the PI3K-Akt pathway, which phosphorylates proline-rich Akt substrate of 40 kDa (PRAS40) to cease mTOR inhibition resulting in increased mTOR signaling. Proliferation assays separated six HNSCC cell lines into two groups: sensitive to EGFR inhibition or resistant; all sensitive cell lines demonstrated reduced sensitivity to EGFR inhibition upon IGF1R activation. Reverse phase protein microarray analysis and immunoblot identified a correlation between increased PRAS40 phosphorylation and IGFR-mediated resistance to EGFR inhibition. In sensitive cell lines, PRAS40 phosphorylation decreased 44%-80% with EGFR inhibition and was restored to 98%-196% of control by IGF1R activation, while phosphorylation was unaffected in resistant cell lines. Possible involvement of mTOR in this resistance mechanism was demonstrated through a similar pattern of p70S6K phosphorylation. However, addition of temsirolimus, an mTORC1 inhibitor, was insufficient to overcome IGF1R-mediated resistance and suggested an alternative mechanism. Forkhead box O3a (FOXO3a), which has been reported to complex with PRAS40 in the cytoplasm, demonstrated a 6-fold increase in nuclear to cytoplasmic ratio upon EGFR inhibition that was eliminated with concurrent IGF1R activation. Transcription of FOXO3a-regulated TRAIL and PTEN-induced putative kinase-1 (PINK1) was increased with EGFR inhibition in sensitive cell lines; this effect was diminished with IGF1R stimulation. IMPLICATIONS: These data suggest PRAS40 may play an important role in IGF1R-based therapeutic resistance to EGFR inhibition, and this likely occurs via inhibition of FOXO3a-mediated proapoptotic gene transcription.

Indexed as

Adaptor Proteins, Signal TransducingCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHumansInsulin-Like Growth Factor IMechanistic Target of Rapamycin Complex 1PhosphorylationProtein Kinase InhibitorsReceptor, IGF Type 1Signal TransductionSirolimusSquamous Cell Carcinoma of Head and NeckTOR Serine-Threonine KinasesAdaptor Proteins, Signal TransducingAKT1S1 protein, humanEGFR protein, humanErbB ReceptorsIGF1R protein, humanInsulin-Like Growth Factor IMechanistic Target of Rapamycin Complex 1MTOR protein, humanProtein Kinase InhibitorsReceptor, IGF Type 1SirolimustemsirolimusTOR Serine-Threonine Kinases

Identifiers

PMID32467173
PMCPMC7483558
OpenAlexW3032234624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.